For Further Information Contact:
Andrew Fisher at (202) 483-7000
Email: Afisher@unither.com

OVAREX® STUDY DEMONSTRATES CLINICAL BENEFIT FOR OVARIAN CANCER PATIENTS

Phase II Trial Shows a Doubling in Progression Free Survival in a Well-Defined Population

Silver Spring, MD and Wellesley, MA, June 2, 2003: Unither Pharmaceuticals, Inc., a wholly owned subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), announced today that Jonathan Berek, MD, Chief of the Division of Gynecologic Oncology UCLA's Jonsson Cancer Center in Los Angeles, presented results of a phase II trial of OvaRex® (oregovamab) at the 39th annual meeting of the American Society of Clinical Oncologists (ASCO) in Chicago. The results of this placebo-controlled trial in stage III/IV ovarian cancer patients identified a population that exhibited a strongly favorable outcome. In this group of patients, median time to disease relapse for OvaRex (n=34) treated patients was 24 months, versus 10.8 months for placebo (n=33) treated patients (p=0.06)

The study was a randomized Phase II multi-center trial assessing the ability of OvaRex to influence time to progression for advanced ovarian cancer patients with no evidence of disease and normalized CA125 following front-line surgery and chemotherapy. Currently there is no approved therapy for patients in this treatment period. The study population was typical of this cancer population, and the treatment arms were well balanced. One hundred forty-five (145) patients were randomized into the study. The clinical outcome favored OvaRex treatment, 13.3 versus 10.3 months in placebo treatment (p=ns), for the primary outcome of time to relapse, as measured by the investigator or independent endpoint monitoring committee. Further analysis of the data revealed a well-defined population that demonstrated a dramatic clinical benefit as compared to placebo. This group is characterized by patients with optimal surgical cyto-reduction, a favorable CA125 response to chemotherapy, and no evidence of disease following chemotherapy. Patients with less favorable outcome and response to surgery and chemotherapy did not appear to benefit from the treatment following front-line chemotherapy. The side effect profile for OvaRex treatment was similar to placebo, unlike most cancer therapeutics, which can have significant toxicity.

"These results, if confirmed in the currently enrolling phase III trials, will address a significant unmet medical need with the promise of an important new therapeutic approach for women with advanced ovarian cancer," said Dr. Jonathan Berek, the Principal Investigator of the study. "The data from this trial offers the potential for a major clinical benefit in the treatment of late stage ovarian cancer."

Unither recently announced the initiation of two identical pivotal Phase III clinical trials, called IMPACT I and II, being conducted at centers throughout the United States. OvaRex®

MAb is an investigational immunotherapeutic monoclonal antibody being developed for the treatment of stage III/IV advanced ovarian cancer following successful completion of front-line therapy. A list of participating sites in the IMPACT I and II trials may be obtained by accessing www.clinicaltrials.gov and entering the keyword: OvaRex.

Ovarian cancer, the deadliest of women's reproductive cancers, is the fifth leading cause of cancer deaths among U.S. women, occurring in 1 out of 57 women. The American Cancer Society estimates that this year, in the United States, there will be 25,400 new cases of ovarian cancer diagnosed, and 14,300 American women will die from this disease. Overall, the five-year survival rate for stage III/IV disease is estimated to be 31%. Although most patients initially respond to surgery and chemotherapy completely, the relapse rate is estimated to be approximately 85%. Once relapse occurs, there is no known curative therapy.

In April 2002, United Therapeutics exclusively licensed OvaRex and four other monoclonal antibody immunotherapies (antibodies that activate a patient's immune response to treat cancer) that were being developed for treatment of ovarian, prostate, lung, breast, multiple myeloma and other forms of cancer, from its strategic partner, AltaRex Corp.

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncological diseases with unique therapeutic products.

This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and more fully described in the reports filed by United Therapeutics with the Securities and Exchange Commission, including the company's most recent Form 10-K and Form 10-Q. United Therapeutics conducts research in the biotechnology field where development from idea to commercial product is uncertain, and there is no guarantee that any particular product candidate will be successfully brought to market. In addition, United Therapeutics' research, development, pricing, distribution and marketing efforts are subject to extensive regulation by United States and international governmental regulatory authorities. United Therapeutics' products are also subject to reimbursement policies imposed by governments, private insurers and managed care providers that may adversely affect product development, usage and pricing. Finally, while United Therapeutics applies for and obtains patents for its products and technologies, such patent protection may be challenged, invalidated or circumvented by others. Because forward-looking statements involve risks and uncertainties, actual results may differ materially from current results expected by United Therapeutics. United Therapeutics is providing this information as of June 2, 2003 and undertakes no obligation to publicly update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

* * *